Patients are avoiding in-person appointments, and fewer hospitals are accepting face-to-face visits with biopharma staff. What does an industry that’s driven by in-person interactions do in the COVID-19 era? According to the Boston Consulting Group, what businesses have always done: adapt. Virtual diagnostics or telemedicine for health care providers, hyper-segmentation and data-driven processes for biopharma companies – these are the development that will see you through the pandemic and ensure your post-COVID success.
About the Authors
Friedemann Wolf, Stephen Waddell, Susan Schriver and Ulrik Schulze are managing directors and partners in the Boston Consulting Group's Hamburg, Chicago, New York and Zurich offices.